Medicinal Products


Generic drug from Zometa
Therapeutic class: Rheumatology
active ingredients: Zoledronic acid
laboratory: Mylan

Solution for solution for IV infusion
Box of 1 bottle of 5 ml
All forms


- Prevention of bone complications (pathological fractures, spinal cord compression, irradiation or bone surgery, tumor-induced hypercalcemia) in adult patients with advanced malignant disease and bone involvement.

- Treatment of tumor-induced hypercalcemia (HIT) in adult patients.

Dosage ZOLEDRONIC ACID MYLAN 4 mg / 5 mL Concentrate for solution for infusion IV Box of 1 vial of 5 ml

Zoledronic acid Mylan should only be prescribed and administered to patients by healthcare professionals who have experience with the administration of intravenous bisphosphonates.


Prevention of bone complications in patients with advanced malignant disease with bone involvement

Adults and elderly subjects

The recommended dose for the prevention of bone complications in patients with advanced malignant bone disease is 4 mg zoledronic acid every 3 to 4 weeks.

Patients should also receive an oral intake of 500 mg of calcium and 400 IU of vitamin D per day.

The decision to treat patients with bone metastases to prevent bone-related complications should be considered taking into account that the time for treatment is 2 to 3 months.

Treatment of tumor-induced hypercalcemia

Adult and elderly subject

The recommended dose for hypercalcemia (albumin-corrected serum albumin ≥12.0 mg / dl or 3.0 mmol / l) is a single dose of 4 mg zoledronic acid.

Renal failure


Treatment with zoledronic acid in patients with tumor-induced hypercalcemia and severe renal impairment should be considered only after assessing the risks and benefits of this treatment. In clinical studies, patients with serum creatinine> 400 μmol / l or> 4.5 mg / dl were excluded. No dose adjustment is required in patients with HIT with serum creatinine <400 μmol / l or <4.5 mg / dl (see Warnings and Precautions ).

Prevention of bone complications in patients with advanced malignant pathology with bone involvement:

Serum creatinine and creatinine clearance (Cl cr ) should be determined when initiating zoledronic acid therapy in patients with multiple myeloma or bone metastases from solid tumors. CL cr is calculated according to the Cockcroft-Gault formula from serum creatinine. Zoledronic acid is not recommended in patients with severe renal impairment prior to initiation of therapy, defined by CL cr 265 μmol / l or 3.0 mg / dl excluded.

In patients with bone metastases with mild to moderate renal impairment prior to initiation of treatment, renal impairment which is defined by a CL cr of 30 to 60 ml / min, the recommended dose of zoledronic acid is as follows (see section Warnings and precautions for use ).

Initial creatinine clearance (ml / min)

Recommended dose of zoledronic acid *

> 60

4.0 mg zoledronic acid


3.5 mg * zoledronic acid


3.3 mg * zoledronic acid


3.0 mg * zoledronic acid

* Doses were calculated to achieve an AUC value of 0.66 (mg.h / l) (for a CL cr = 75 ml / min). The aim is that in patients with renal impairment, reduced doses of zoledronic acid will achieve the same AUC as observed in patients with a creatinine clearance of 75 ml / min.

After initiation of treatment, serum creatinine should be measured before each administration of zoledronic acid and treatment should be discontinued if renal function has deteriorated. In clinical studies the impairment of renal function was defined as follows:

- An increase of 0.5 mg / dl or 44 μmol / l in patients who had a baseline creatinine value (<1.4 mg / dl or <124 μmol / l).

- An increase of 1.0 mg / dL or 88 μmol / L in patients who had an abnormal baseline creatinine value (> 1.4 mg / dL or> 124 μmol / L).

In clinical studies, treatment with zoledronic acid was resumed only when the serum creatinine value returned to the baseline ± 10% (see Warnings and Precautions ). Treatment with zoledronic acid should be resumed at the same dose as before treatment discontinuation.

Pediatric population

The safety and efficacy of zoledronic acid in children aged 1 to 17 years has not been established. Currently available data are described under Pharmacodynamic properties, but no dosage recommendation can be made.

Administration mode

Intravenous way.

Zoledronic acid Mylan 4 mg / 5 ml concentrate for solution for infusion, then diluted in 100 ml (see section Instructions for use, handling and disposal ), should be administered as a single intravenous infusion over a period of at least 15 minutes.

In patients with mild to moderate renal impairment, reduced doses of zoledronic acid are recommended (see section "Posology" above).

Instructions for preparing reduced doses of Zoledronic Acid Mylan

Take an appropriate volume of the concentrated solution as follows:

- 4.4 ml for a dose of 3.5 mg

- 4.1 ml for a dose of 3.3 mg

- 3.8 ml for a dose of 3.0 mg

The amount taken from the concentrated solution should then be diluted in 100 ml sterile 9 mg / ml sodium chloride (0.9%) solution for injection or 5% w / v glucose solution. The dose should be administered as an intravenous infusion lasting at least 15 minutes.

Zoledronic acid Mylan concentrate for infusion should not be mixed with solutions containing calcium or other infusion solutions containing divalent cations such as lactated Ringer's solution and should be administered in a dissociated manner from other infusions via a separate line.

Patients should be properly hydrated before and after zoledronic acid administration.

Against indications

Hypersensitivity to the active substance, to other bisphosphonates or to any of the excipients listed under Composition .

- Breastfeeding (see section Pregnancy and breastfeeding )

Side effects Zoledronic acid Mylan

Summary of the security profile

An acute phase reaction, occurring within three days of zoledronic acid administration and manifesting as symptoms, including bone pain, fever, fatigue, arthralgia, myalgia, and chills, has been reported frequently; these symptoms usually resolve within a few days (see description of selected side effects).

The significant risks identified with zoledronic acid in approved indications are as follows:

Impairment of renal function, osteonecrosis of the jaw, acute reaction phase, hypocalcemia, ocular adverse effects, atrial fibrillation, anaphylaxis. The frequency of each of these identified risks is presented in Table 1.

Table of adverse effects

The following adverse reactions, listed in Table 1, were collected in clinical studies and post-marketing reports of post-marketing experience, mainly after chronic administration of zoledronic acid 4 mg:

Table 1

Adverse effects are ranked in order of decreasing frequency using the following convention:

Very common (≥ 1/10)

Frequent (≥ 1/100, <1/10)

Uncommon (≥1 / 1, 000, <1/100)

Rare (≥ 1 / 10, 000, <1 / 1, 000)

Very rare (<1 / 10, 000)

Not known (can not be estimated from the available data).

Blood and lymphatic system disorders




Thrombocytopenia, leukopenia



Immune system disorders


Hypersensitivity reaction


Quincke's edema (angioneurotic)

Psychiatric disorders


Anxiety, sleep disorders



Nervous system disorders




Dizziness, paresthesia, taste disturbance, hypoesthesia, hyperesthesia, tremors, drowsiness

Eye disorders




Blurred vision, scleritis and orbital inflammation

Very rare

Uveitis, episcleritis

Heart conditions


Hypertension, hypotension, atrial fibrillation, hypotension may lead to syncope or circulatory collapse



Respiratory, thoracic and mediastinal disorders


Dyspnoea, cough, bronchoconstriction

Gastrointestinal disorders


Nausea, vomiting, anorexia


Diarrhea, constipation, abdominal pain, dyspepsia, stomatitis, dry mouth

Skin and subcutaneous tissue disorders


Pruritus, rash (including erythematous and macular eruptions), increased sweating

Musculoskeletal and systemic disorders


Bone pain, myalgia, arthralgia, generalized pain


Muscle cramps, osteonecrosis of the jaw *

Renal and urinary disorders


Renal impairment


Acute renal failure, hematuria, proteinuria

General disorders and administration site conditions


Fever, flu-like symptoms (including fatigue, chills, malaise and flushing)


Asthenia, peripheral edema, injection site reactions (including pain, irritation, swelling, induration), chest pain, weight gain, anaphylactic shock, urticaria


Very common



Increased serum creatinine and serum calcium, hypocalcemia


Hypomagnesemia, hypokalemia


Hyperkalemia, hypernatremia

* Based on clinical trials with review of possible cases of osteonecrosis of the jaw. Because these reports are confounding, it is not possible to reliably establish a causal relationship to drug exposure.

Description of selected adverse reactions

Impairment of renal function

Impaired renal function has been reported with zoledronic acid. In a pooled analysis of safety data from registration studies in patients with advanced bone marrow malignancies treated for the prevention of musculoskeletal events, the frequency of suspected renal failure to be related to zoledronic acid (adverse effects) was: multiple myeloma (3.2%), prostate cancer (3.1%), breast cancer (4.3%), lung tumors and other solid tumors (3.2%). Factors that may increase the risk of deterioration of renal function are dehydration, pre-existing renal impairment, repeated cycles of zoledronic acid or other bisphosphonates, concomitant use of nephrotoxic drugs and shorter infusion time than the recommended one. Impairment of renal function, progression of renal failure and dialysis have been reported in patients following the first dose or a single dose of 4 mg zoledronic acid (see Warnings and Precautions section). )

Osteonecrosis of the jaw

Cases of osteonecrosis (mainly jaw) have been reported, mainly in patients with cancer treated with drugs that inhibit bone resorption, such as zoledronic acid. Many of these patients showed signs of local infection including osteomyelitis, and the majority of cases involved cancer patients who underwent tooth extraction or other dental surgeries. Osteonecrosis of the jaw has multiple documented risk factors including diagnosis of cancer, associated treatments (eg, chemotherapy, radiotherapy, corticosteroids) and associated conditions (eg, anemia, bleeding disorders, infection pre-existing oral disease). Although causality has not been established, it is recommended that dental surgery be avoided and that healing may be delayed (see Warnings and Precautions section ).

Atrial fibrillation

In a 3-year, randomized, double-blind controlled trial that evaluated the efficacy and safety of 5 mg once-yearly zoledronic acid versus placebo in the treatment of postmenopausal osteoporosis (OPM), the overall incidence of atrial fibrillation was 2.5% (96/3862) in the zoledronic acid arm and 1.9% (75/3852) in the placebo arm. The rate of atrial fibrillations classified as serious adverse events was 1.3% (51/3862) in the zoledronic acid arm and 0.6% (22/3852) in the placebo arm. The imbalance observed in this study was not observed in other studies with zoledronic acid, including those with zoledronic acid 4 mg given every 3-4 weeks in patients treated oncology. The mechanism of the increase of this incidence of atrial fibrillation in this single clinical study is not known.

Acute phase reaction

This side effect consists of a constellation of symptoms that include fever, myalgia, headache, extremity pain, nausea, vomiting, diarrhea, and arthralgia. The time to onset of these symptoms is ≤ 3 days after infusion of zoledronic acid. All of these symptoms can be presented as "flu-like" or "post-dose" symptoms.

Atypical fractures of the femur

After commercialization, the following adverse reactions have been reported (rare frequency): atypical subtrochanteric and diaphyseal femoral fractures (class-related bisphosphonate side effects).

Popular Posts

Category Medicinal Products, Next Article